March 22, 2013 at 08:35 AM EDT
UPDATE: ARIAD Confirms Positive CHMP Opinion for Iclusig Approval in EU
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA ) today announced that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authorization application for Iclusig™ (ponatinib) for two indications: * The treatment of adult patients with chronic phase, accelerated phase or
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here